NSAIDs-induced gastrointestinal damage: Review

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 3, 2006, Pages 249-259

  Arroyo, M ^a   Lanas, A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Coxibs; Gastrointestinal bleeding; Helicobacter pylori; Non steroidal anti inflammatory drugs; Peptic ulcer

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; KETOROLAC; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; REFECOXIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTHRITIS; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DYSPEPSIA; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH ULCER; SYSTEMATIC REVIEW; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; RISK FACTORS;

EID: 33750609708     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Wallace J. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:1000-16.
2. Hirschowitz B, Lanas A. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999;11:375-81.
3. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropiate use of non-steroidal anti-inflammatory drugs, cyclo-oxigenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004;19:197-208.
4. Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004;19 Suppl 1:60-5.
5. Laine L. Approaches to non-steroidal anti-inflammatory drug use in the high-risk patients. Gastroenterology 2001;120:594-606.
6. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18-24.
7. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
8. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
9. Hernandez S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000;160:2093-9.
10. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
11. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis D et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
12. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-32.
13. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.
14. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685-93.
15. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
16. Hawkey C, Lanas A. Doubt and certainty about NSAIDs in the year 2000; a multidisciplinary expert statement. On behalf of the Sardinia NSAID meeting participants. Am J Med 2001;110 Suppl 1:S79-S100.
17. Singh G, Ramey DR, Terry R, Khraishi M, Triadafilopoulos G. NSAID-related effects on the GI tract: an ever widening spectrum. Arthritis Rheum 1997;40 Suppl:S93.
18. Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects. Med Clin 2000;114 Suppl 3:46-53.
19. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
20. Brun J, Jones R. Non-steroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001;110:12S-13S.
21. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
22. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54.
23. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19.
24. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
25. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
26. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449-58.
27. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986;104:390-8.
28. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24 Suppl 49:6-8.
29. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136-8.
30. Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ 1989;298:493-6.
31. Kitchingman GK, Prichard PJ, Daneshmend TK, Walt RP, Hawkey CJ. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine. Br J Clin Pharmacol 1989;28:581-5.
32. Day JP, Lanas A, Rustagi P, Hirschowitz BI. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J Clin Gastroenterol 1996;22:96-103.
33. Lanas A, Arroyo MT, Esteva F, Cornudella R, Hirschowitz BI, Sainz R. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 1996;39:654-60.
34. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
35. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-40.
36. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
37. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
38. Stack WA, Hawkey GM, Atherton JC, Logan RF, Hawkey CJ. Interaction of risk factors for peptic ulcer bleeding. Gastroenterology 1999;116:A97.
39. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
40. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
41. Gray SL, Sager M, Lestico MR, Jalaluddin M. Adverse drug events in hospitalized elderly. J Gerontol Med Sci 1998;53A:M59-M63.
42. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107-16.
43. Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol 2006;62:65-73.
44. Lanas A, Ferrandez A. Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 2002;1:245-52.
45. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999;116:1305-9.
46. Huang JQ, Lad RJ, Sridhar S, Sumanac K, Hunt RH. H. pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID)-induced gastro-duodenal ulceration. Gastroenterology 1999;116:A192.
47. Santolaria S, Lanas A, Benito R, Perez-Aisa MA, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;16:1511-8.
48. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
49. Stack WA, Hawkey GM, Atherton JC, Logan RF, Hawkey CJ. Interaction of risk factors for peptic ulcer bleeding. Gastroenterology 1999:116:A97.
50. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
51. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
52. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
53. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez Perez A et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006; [Epub ahead of print].
54. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
55. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
56. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
57. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
58. Lanas A. Prevention and treatment of NSAID-induced gastroduodenal Injury. Curr Treat Options Gastroenterol 2006;9:147-56.
59. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2004;4(CD002296):1-111.
60. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
61. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948-57.
62. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL et al.; NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169-75.
63. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
64. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
65. Chan F, Ching JY, Hung LC, Wong VW, Leung VK, Kung NM et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44.
66. Chan FK, Hung LC, Suen BY, WuJC, Lee KC, Leung VK et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
67. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005;118:1271-8.
68. Lanas A, Martin-Mola E, Ponce J, Navarro F, Pique JM, Blanco FJ. Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents. Gastroenterol Hepatol 2003;26:485-502.
69. Chan FKL, Wong VW, Suen BY, Wu JC, Leung WH, Le YT et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis. A double blind, randomized trial. Gastroenterology 2006;130(4 part 2):A732.
70. Lanas A, García-Rodriguez LA, Arroyo MT, Gomollón F, Feu F, Forné M et al. Effects of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with NSAIDs and anti-platelet agents. Gastroenterology 2006;130:A563.
71. Rahme E, Dasgupta K, Toubouti Y, Barkoun AN, Bardou M. GI effect of rofecoxib and celecoxib versus NSAID in patients on low dose aspirin, a population-based retrospective cohort study. Gastroenterology 2004;126:17.
72. Huang JQ, Sridhar L, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
73. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
74. Hawkey CJ, Tulassay Z, Szczepanski L, Van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study Lancet 1998;352:1016-21.
75. Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Langstrom G et al.; NASA1 SPACE1 Study Group. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005;100:1028-36.
76. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.
77. Lai K, Hui W, Wong B, Hu W, Chan O, Lam S. Lansoprazole but not rofecoxib reduced dyspeptic symptoms of patients on NSAIDs. Gastroenterology 2005;128:137A.
78. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut 1996;39:22-6.
79. Lanas A. Review article: recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs: a gastroenterologist's perspective. Aliment Pharmacol Ther 2005;1:16-9.